Background: Maintenance medications provide symptomatic relief, improve lung function and reduce the risk of exacerbations in patients with chronic obstructive pulmonary disease (COPD). Despite their proven benefits, limited information exists on maintenance medication use and adherence among users. Objective: We examined the patterns and factors associated with the receipt of and adherence to maintenance medication in individuals with COPD. Methods: A retrospective cross-sectional study of 5% of Medicare beneficiaries enrolled in Parts A, B and D with COPD who received maintenance medication from 2008 to 2013 was conducted. Maintenance medication includes: inhaled corticosteroids (ICSs), long-acting beta2-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) alone or in combination. We examined the proportion of beneficiaries with COPD who had at least one prescription filled for maintenance medication. Among users of maintenance medications, we also examined adherence, defined as proportion of days covered (PDC) ≥80% over the year from the first maintenance medication prescription fill date. The overall adherence among maintenance medication users remained flat. The most important factor associated with adherence was dual eligibility status (OR, 1.67; 95% CI:
Introduction
Pharmacological management of patients with chronic obstructive pulmonary disease (COPD) is based on symptoms, disease severity and risk of exacerbation. Long-acting muscarinic antagonists (LAMAs), longacting beta2-agonists (LABAs), phosphodiesterase (PDE-4) inhibitors and the combinations fixed-dose inhaled corticosteroids (ICSs) with a LABA and LABA/ LAMA are approved as maintenance medications to manage patients with moderate to severe COPD.
1 These medications have been shown to provide symptomatic relief, improve lung function and reduce the risk of exacerbations.
1-3
Current knowledge of the use of and adherence to maintenance medication comes from randomized controlled trials. [4] [5] [6] In the real-world setting, adherence to clinical practice guidelines is low in patients with COPD. 7, 8 The high burden of comorbidities, complex inhaler regimens, co-existing psychosocial disorders and cost all negatively impact adherence.
9-15 Moreover, a high proportion of patients prescribed these medications have not undergone spirometry to confirm the diagnosis of COPD.
16 In general, patients with COPD are undertreated.
17
We used a 5% national sample of Medicare beneficiaries with COPD to examine the pattern of maintenance medication use and adherence among maintenance medication users from 2008-2013. We also examined factors associated with the receipt of and adherence to maintenance medication. Our hypothesis was that the overall use of maintenance medication would increase during the study period, but the magnitude of increase would be impacted by the financial burden to the patient.
Data Source
This is a retrospective, cross-sectional study of maintenance medication use in individuals with COPD using a 5% Medicare beneficiary population, 2008-2013. This study was approved by the University of Texas Medical Branch Institutional Review Board and informed consent was waived due to the nature of the study. Over 98% of adults in the United States age ≥65 years are enrolled in Medicare, which includes >45 million beneficiaries. The Centers for Medicare and Medicaid Services selects a random sample of 5% Medicare beneficiaries based on the eighth and ninth digits (05, 20, 45, 70, 95) of their health insurance claim number. The resulting standard data is available for research purposes and has been shown to be representative of the entire cohort.
18
Data from the following files were used for this study: 1) Denominator file (Medicare enrollment information and demographic data); 2) Medicare Provider Analysis and Review file (claims for hospital inpatient and skilled nursing facility stays); 3) Outpatient Standard Analytic File (hospital outpatient services); 4) 100% Physician/Supplier file (physician and other medical services); 5) Durable Medical Equipment (DME) file; and 6) Part D Drug Event file. The education level at the zip code of residence was obtained from the American Community Survey estimates of the U.S. Census. A comorbidity score (0, 1, 2, ≥3) was generated using the Elixhauser comorbidity score (excluding COPD) from inpatient and outpatient billing data.
Study Cohort

19
A spirometry examination was identified through Current Procedural Terminology codes (94010, 94014, 94015, 94016, 94060, 94070, 94620) . Oxygen therapy use was defined from Healthcare Common Procedure Coding System codes E1390-E1392. Outpatient pulmonary specialist visit was defined as any outpatient visit with a Health Care Financing Administration provider specialty code ("29") during the study year.
Outcome Measures
Our outcomes of interest were receipt of COPD maintenance medication and maintenance medication adherence in each study year of interest for individuals with COPD. The COPD maintenance medications included LABAs, LAMAs, ICSs, and fixed-dose LABA/ ICS combinations. Medication prescriptions and prescribed dosages were extracted from Part D and DME prescriptions filled. We chose to look at DME files as nebulized medication is covered under DME benefits. For each year, the proportion of days covered (PDC), defined as the proportion of days in a study year that a patient had COPD maintenance medication available from the index prescription filled date, was calculated. The index date was defined as the earliest date a maintenance medication prescription was filled during the study year. For prescriptions extending beyond the end of the year, the days covered were truncated at the end of the year. Beneficiaries were classified as adherent if their PDC ≥80%.
Statistical Analysis
Patient characteristics were summarized from 2008-2013 using counts and percentages of categorical variables. A generalized estimate equation (GEE) with binomial distribution model analysis was used to assess the trend in outcomes, adjusted for patient characteristics (age, gender, race, dual eligibility status, education level and comorbidity) and health care measures (COPD hospitalization in the previous year, having a spirometry test, oxygen therapy treatment and pulmonary specialist visit). The GEE accounted for the cluster effect of individuals.
20 A priori 2-way interactions on maintenance medication use and adherence was tested between dual eligibility status and education level, and between dual eligibility and study years. All analyses were performed using SAS version 9.4 (SAS Inc., Cary, North Carolina). All reported p-values were two-sided with p<0.05 considered statistically significant. Table 1 presents the baseline characteristics of beneficiaries with COPD by study year. The number of individuals with COPD increased from 13,957 to 18,044. The majority were female, non-Hispanic white and had ≥2 comorbidities. Over a third of beneficiaries were prescribed home oxygen therapy, were seen by a pulmonary specialist and had spirometry testing. During the entire study period, a higher percentage of beneficiaries with dual eligibility status had maintenance medications filled compared to those who had Medicare only, suggesting that co-payment or deductible plays a role in the use of higher cost prescriptions. To examine adherence (B), we performed a subset analysis using beneficiaries who filled a prescription of any maintenance medication during the calendar year. As shown in the figure, individuals with dual eligibility status had a higher mean PDC over the study period, but the mean PDC of either group did not change over the study period. • the largest increases can be attributed to increased LABA/ICS combination therapy;
• dual eligible (i.e., dual eligibility status) beneficiaries with COPD are more likely to receive a maintenance medication prescription and had a higher rate of increase in receipt of maintenance medications over time.
• Overall adherence to maintenance medication in this population remains suboptimal. For effective chronic disease management of COPD, appropriate use of recommended prescription medication is crucial.
21 Studies show low use of and adherence to COPD maintenance medication.
8,10
Patient-related factors associated with risk of poor adherence include unemployment status, less education, low income, living alone and psychosocial comorbidity.
13 Cross sectional and longitudinal
Discussion
The results of our study can be summarized as follows:
• studies examining the role of depression in adherence to COPD maintenance medication have shown that adherence to COPD maintenance medication falls precipitously within 6 months of use and depression is associated with lower adherence compared to those without depression.
10,22,23
Other factors related to lower COPD maintenance medication adherence include lack of perceived or actual benefit from the prescribed medication, 12,23 inability to follow instructions either due to cognitive 15 or physical inability to use different inhalation devices and out-ofpocket cost of these medications.
11,14,24
In our study, women were more likely than men to get a prescription for a maintenance medication. However, their adherence to maintenance medication was similar to that of men. This is congruent with prior reports which also showed no association between gender and adherence. 8, 12 One study did show lower adherence in women, but results were confounded by the higher prevalence of depression in women, as the latter is associated with lower adherence.
10
Our findings of increased maintenance medication use in dual eligible individuals with COPD are worth exploring. Currently, none of the COPD maintenance medications are generic or covered under $4 generic prescription programs. However, dual eligible beneficiaries pay no premium and face no deductible under Part D, making these medications affordable under the plan. Beneficiaries who are not dual eligible may not be able to afford these medications. This situation is similar to that of cardiovascular prescriptions in which dual eligible beneficiaries are shown to have higher adherence.
25
Potential strategies to improve medication adherence will be most successful if undertaken within a multidimensional approach. As shown in our study, the increased adherence over time of dual eligible beneficiaries supports the importance of medication coverage. Health care policy changes should focus on value-based insurance plans and improved prescription drug coverage for Medicare Part D beneficiaries, of whom 17% enter the coverage gap by October. 24 Providers should personalize inhaler devices to optimize medication use and delivery, 11 reduce the complexity of medication regimens whenever possible, 8, 14 decrease the number of device types prescribed 26 and instill inhaler competency for themselves in order to educate patients.
27-29
Pharmacist-led interventions may include inhaler education and medication synchronization, where all patients' prescriptions are filled on the same day and scheduled closer to the receipt of their income payment.
30-32 Treatments should ideally include the right medication-device combination for patients rather than a manufacturer proprietary device or insurance formulary determining the availability of a specific medication. Finally, monitoring and feedback about inhaler use through electronic medication delivery devices may assist in medication adherence.
32
Limitations
Our study has several limitations. The analysis is limited to fee-for-service Medicare beneficiaries who had Medicare Parts A, B and D and is nongeneralizable to managed Medicare or commercial insurance populations with COPD. Actual spirometry values and dyspnea scores cannot be assessed using administrative claims to verify a diagnosis or severity of COPD. However, we used surrogates for disease severity such as oxygen use, prior COPD hospitalization and clinic assessment by a pulmonary physician. The medication "use" is based on a prescription filled. This does not account for medications prescribed and never filled or medications used appropriately. Dual eligibility status is based on Medicaid coverage for at least 1 month during the entire year and may not be a true representation of the patient's poverty status. Nonetheless, this measure is shown to be a good surrogate of the socioeconomic status of Medicare beneficiaries.
33
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